Start Time: 16:30 January 1, 0000 5:02 PM ET

BioLife Solutions, Inc. (NASDAQ:BLFS)
Q1 2024 Earnings Conference Call
May 09, 2024, 16:30 PM ET

Company Participants

Rod de Greef - Chairman and CEO
Troy Wichterman - CFO
Garrie Richardson - Chief Revenue Officer

Conference Call Participants

Paul Knight - KeyBanc
Hannah Hefley - Stephen Inc.
Matthew Stanton - Jefferies
Matt Hewitt - Craig-Hallum Capital Group
Thomas Flaten - Lake Street Capital

Operator

Welcome to the BioLife Solutions First Quarter 2024 Financial Results and Business Update. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session.

I would now like to turn the call over to your host, Troy Wichterman, Chief Financial Officer. Troy, you may begin.

Troy Wichterman

Thank you, operator. Good afternoon everyone and thank you for joining the BioLife Solutions 2024 first quarter earnings conference call. On this call, we will cover business highlights and financial performance for the quarter and reiterate our previous comments on full year 2024 revenue guidance. Earlier today, we issued a press release announcing our financial results and operational highlights for the first quarter of 2024, which is available at biolifesolutions.com.

As a reminder, during this call, we will make forward-looking statements. These statements are subject to risks and uncertainties that can be found in our SEC filings. These statements speak only as of the date given, and we undertake no obligation to update them. We will also speak to non-GAAP or adjusted results. Reconciliations of GAAP to non-GAAP or adjusted financial metrics are included in the press release we issued this afternoon.

Now, I'd like to turn the call over to Rod de Greef, Chairman and CEO of BioLife.

Rod de Greef

Thanks, Troy. Good afternoon, and thank you for joining us for BioLife's first quarter 2024 earnings call. In addition to Troy Wichterman, our CFO, I've invited Garrie Richardson, our Chief Revenue Officer, who will provide additional granularity on our Q1 revenue numbers and end market dynamics. He will also speak to our expertise and our strategy to continue to grow our market-leading franchise in biopreservation.

To begin, I'm pleased to report another quarter of sequential revenue growth in our core cell processing business and increased confidence in our full year outlook of 95.5 million to 100 million in revenue. While early in the year, it's an encouraging start and helps substantiate our belief that we are now beginning to experience an easing macro environment, particularly in the bioproduction subsector we operate in.